rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
19
|
pubmed:dateCreated |
1999-2-2
|
pubmed:abstractText |
A series of novel selective phosphodiesterase 4 (PDE4) inhibitors has been developed which displays activity both in vitro and in vivo. These compounds possess good selectivity for the catalytic site of PDE4 over the high affinity Rolipram binding site. In vivo studies demonstrate a reduced propensity to display the emetic side effects which are commonly observed with PDE4 inhibitors.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0960-894X
|
pubmed:author |
pubmed-author:BuckleyG MGM,
pubmed-author:CooperNN,
pubmed-author:DykeH JHJ,
pubmed-author:GowersLL,
pubmed-author:GregoryJ PJP,
pubmed-author:HellewellP GPG,
pubmed-author:KendallH JHJ,
pubmed-author:LoweCC,
pubmed-author:MaxeyRR,
pubmed-author:MiotlaJJ,
pubmed-author:MontanaJ GJG,
pubmed-author:NaylorR JRJ,
pubmed-author:RuncieK AKA,
pubmed-author:TuladharBB,
pubmed-author:WarneckJ BJB
|
pubmed:issnType |
Print
|
pubmed:day |
6
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2635-40
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9873594-3',5'-Cyclic-AMP Phosphodiesterases,
pubmed-meshheading:9873594-Animals,
pubmed-meshheading:9873594-Anti-Asthmatic Agents,
pubmed-meshheading:9873594-Cyclic Nucleotide Phosphodiesterases, Type 4,
pubmed-meshheading:9873594-Eosinophilia,
pubmed-meshheading:9873594-Guinea Pigs,
pubmed-meshheading:9873594-Phosphodiesterase Inhibitors,
pubmed-meshheading:9873594-Pyrrolidinones,
pubmed-meshheading:9873594-Rolipram,
pubmed-meshheading:9873594-Structure-Activity Relationship,
pubmed-meshheading:9873594-Sulfonamides
|
pubmed:year |
1998
|
pubmed:articleTitle |
Aryl sulfonamides as selective PDE4 inhibitors.
|
pubmed:affiliation |
Chiroscience Ltd, Cambridge, UK. johnmontana@chiroscience.com
|
pubmed:publicationType |
Journal Article
|